| A randomized, controlled trial of the renal effects of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure HL Rogers, J Marshall, J Bock, TC Dowling, E Feller, S Robinson, ... Journal of cardiac failure 14 (1), 1-5, 2008 | 141 | 2008 |
| The U.S. Food and Drug Administration's Experience with Ivacaftor in Cystic Fibrosis. Establishing Efficacy Using In Vitro Data in Lieu of a Clinical Trial AG Durmowicz, R Lim, H Rogers, CJ Rosebraugh, BA Chowdhury Annals of the American Thoracic Society 15 (1), 1-2, 2018 | 109 | 2018 |
| CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the US Food and Drug Administration's new dosing recommendations HL Rogers, A Bhattaram, I Zineh, J Gobburu, M Mathis, TP Laughren, ... The Journal of clinical psychiatry 73 (9), 4005, 2012 | 49 | 2012 |
| Allopurinol pharmacogenetics: assessment of potential clinical usefulness I Zineh, P Mummaneni, J Lyndly, S Amur, LA La Grenade, SH Chang, ... Pharmacogenomics 12 (12), 1741-1749, 2011 | 49 | 2011 |
| Consistency of drug–drug and gene–drug interaction information in US FDA-approved drug labels DJ Conrado, HL Rogers, I Zineh, MA Pacanowski Pharmacogenomics 14 (2), 215-223, 2013 | 41 | 2013 |
| Clinical pharmacology studies supporting oligonucleotide therapy development: an assessment of therapies approved and in development between 2012 and 2018 H Rogers, O Adeniyi, A Ramamoorthy, S Bailey, M Pacanowski Clinical and Translational Science 14 (2), 468-475, 2021 | 17 | 2021 |
| Clinical and regulatory considerations in pharmacogenetic testing RN Schuck, E Marek, H Rogers, M Pacanowski American Journal of Health-System Pharmacy 73 (23), 1999-2006, 2016 | 15 | 2016 |
| How informative are drug‐drug interactions of gene‐drug interactions? CV Lagishetty, J Deng, LJ Lesko, H Rogers, M Pacanowski, S Schmidt The Journal of Clinical Pharmacology 56 (10), 1221-1231, 2016 | 15 | 2016 |
| Clinical Pharmacology of RNA Interference–Based Therapeutics: A Summary Based on Food and Drug Administration–Approved Small Interfering RNAs X Jing, V Arya, KS Reynolds, H Rogers Drug Metabolism and Disposition 51 (2), 193-198, 2023 | 12 | 2023 |
| Association of genetic mutations and loss of ambulation in childhood‐onset dystrophinopathy G Haber, KM Conway, P Paramsothy, A Roy, H Rogers, X Ling, ... Muscle & nerve 63 (2), 181-191, 2021 | 12 | 2021 |
| Considerations for developing targeted therapies in low‐frequency molecular subsets of a disease RN Schuck, J Woodcock, I Zineh, P Stein, J Jarow, R Temple, T Permutt, ... Clinical Pharmacology & Therapeutics 104 (2), 282-289, 2018 | 12 | 2018 |
| Assessment of the immunogenicity potential for oligonucleotide-based drugs SP Henry, C Arfvidsson, J Arrington, J Canadi, D Crowe, S Gupta, ... nucleic acid therapeutics 32 (5), 369-377, 2022 | 6 | 2022 |
| Clinical pharmacology of RNAi-based therapeutics: a summary based on FDA-approved small-interfering RNAs X Jing, V Arya, KS Reynolds, H Rogers Drug Metabolism and Disposition, 2022 | 4 | 2022 |
| An integrated clinical pharmacology approach for deriving dosing recommendations in a regulatory setting: Review of recent cases in psychiatry drugs IR Younis, H Rogers, H Zhang, H Zhu, RS Uppoor, MU Mehta The Journal of Clinical Pharmacology 53 (10), 1005-1009, 2013 | | 2013 |
| The role of the beta-1 adrenergic receptor SNPs, in the treatment of heart failure with beta-blockers H Rogers, T Dowling, S Liggett, S Gottlieb, S Robinson JOURNAL OF CLINICAL PHARMACOLOGY 48 (9), 1116-1116, 2008 | | 2008 |
| UNLOAD Response to Letter to the Editor SS Gottlieb, HL Rogers Journal of Cardiac Failure 14 (6), 534-534, 2008 | | 2008 |
| A Randomized, Controlled Trail of the Renal Effects of Ultrafiltration as Compared to Furosemide H Rogers, J Marshall, J Bock, T Dowling, E Feller, S Robinson, ... Journal of Cardiac Failure 13 (6), S139, 2007 | | 2007 |
